Generated by AI
Metagenomi Therapeutics, Inc. is a precision genetic medicines company focused on in vivo genome editing for the development of curative therapies. The company uses a proprietary metagenomics-derived toolbox to discover and engineer genome-editing systems, including nucleases, base editors, and gene-integration technologies. Its platform is designed to support precise DNA changes across a wide range of genetic targets, with current work centered on therapeutic programs for serious inherited conditions such as hemophilia and other genetic diseases. Metagenomi Therapeutics also collaborates with partners in biotechnology and pharmaceutical research to expand the potential uses of its editing technologies. Headquartered in Emeryville, California, Metagenomi Therapeutics, Inc. plays a role in the growing field of next-generation genetic medicine, where genome editing is being developed as a foundational approach to treating disease at its source.
Website5959 Horton Street
EmeryVille, CA, 94608
United States
The latest articles about MGX.
EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a fireside chat at the Jefferies Global Healthcare Conference, being held in London, UK, on Wednesday, November 18, 2026, at 12:00 p.
Summary of May 9's posts. Generated by AI.
Summary of Dec 10's posts. Generated by AI.
Summary of Feb 20's posts. Generated by AI.
No summary yet.
Summary of Sep 7's posts. Generated by AI.
Investors talking about MGX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.